Amicus Therapeutics Business Model Canvas

Patient advocacy groups and foundations accelerate patient identification, education and trial awareness—critical for rare diseases like Fabry, which affects about 1 in 40,000 males; globally ~300 million people live with rare diseases (WHO). Foundations inform unmet needs and patient-reported outcomes used in study design and registries. Advocacy input strengthens access strategies and policy engagement, while co-created programs improve adherence and real-world evidence generation.

Academic and rare-disease centers supply well-characterized cohorts and natural history datasets to de-risk trials. CMOs ensure GMP manufacturing with dual sourcing becoming standard by 2024 to secure supply and scale. Advocacy groups and diagnostics expand ID/enrollment; Fabry ~1 in 40,000 males and rare diseases affect ~300 million globally.

Process development ensures potency and batch-to-batch consistency for Amicus biologics and small molecules, using standardized assays and release criteria. GMP oversight covers suppliers, contract manufacturing organizations, and distribution partners to secure product quality and traceability. Continuous validation programs and document control maintain regulatory compliance across markets. Technology transfers to regional sites enhance supply resilience and reduce single‑source risk.

Discovery and preclinical work targets lysosomal and genetic disorders, supporting a pipeline of over 10 preclinical and clinical programs as of 2024 and leveraging Galafold approvals in the US, EU and Japan (Galafold approved 2018). Candidate optimization, biomarker-driven enrollment and GMP process development advance clinical readiness and commercial quality. Regulatory submissions (NDA/MAA), pharmacovigilance, HTA, patient services and launch ops sustain product lifecycle.

Experts in genetics, enzymology and rare-disease care drive Amicus innovation, targeting areas within the >7,000 known rare diseases that affect ~300 million people worldwide. Field teams systematically engage metabolic specialists and geneticists to accelerate patient identification and enrollment. KOLs advise on trial design and care pathways, while cross-functional teams ensure agile execution across R&D, clinical and commercial functions.

Amicus’ core assets (Galafold commercial in 50+ countries; AT-GAA late-stage) drive revenue and pipeline optionality. Global IP >1,000 patents/applications (2024) and trade secrets protect value. Pooled trials + registries and RWE (2024) underpin access and guidelines. Validated CMOs, cold-chain (2–8°C/−80°C) and ≥2 regional sites secure supply.

Therapies such as migalastat are genotype-guided, approved for patients with amenable GLA variants (EU approval 2016, US approval 2018), aligning treatment to specific mutations and biomarkers. Companion diagnostic sequencing determines amenability, improving selection and response rates by targeting patients with responsive variants. Personalized approaches minimize unnecessary exposure to nonbeneficial therapies, and published trial outcomes used in regulatory review reinforce tailored care.

Amicus offers disease-modifying, genotype-guided therapies like migalastat that target underlying enzyme misfolding in Fabry, improving organ function and quality of life. Oral chaperone therapy reduces infusion burden and provider costs versus biweekly ERT. Real-world data show durable biochemical/clinical response up to 5 years, supporting value-based contracting.

Medical affairs delivers non-promotional, balanced data through congress symposia and targeted MSL visits that address clinicians’ specific questions and unmet needs. Digital libraries provide on-demand resources for HCPs and patients, enabling rapid access to protocols, safety data and real-world evidence. Insights gathered from engagements feed into post-marketing studies and future trial design to close evidence gaps.

Dedicated case managers enable rapid-start therapy (as fast as 48 hours) and real-time monitoring linked to ~20% higher adherence. KOL/COE partnerships and early-access programs in 2024 bolster uptake and reimbursement; 62% of payers rely on RWE. Outcomes contracts and pilots reduced first-year budget impact ~15% and advocacy reached 3,000 participants.

Account managers and MSLs engage metabolic and genetic specialists to support GALAFOLD (migalastat), an FDA‑approved Amicus therapy for Fabry disease, focusing in‑office education on dosing and monitoring. Sample programs and starter kits streamline initiation and reimbursement workflow. Field feedback cycles into updated educational materials and KOL outreach to refine uptake. Amicus remains a commercial‑stage rare disease company.

Controlled specialty-pharmacy distribution, hub prior‑authorization workflows and real‑time inventory/clinical feeds secure cold‑chain handling and access for GALAFOLD (migalastat) (FDA‑approved). Site‑of‑care programs and infusion suites coordinate multidisciplinary rare‑disease pathways, with site‑cost reductions up to 40% in 2023–24 analyses. HCP portals, MSLs and tele‑support drive uptake, adherence monitoring and capture PROs; 2024 peer‑reviewed data support guideline inclusion.

Hospitals and centers of excellence manage complex diagnostics, infusions, and longitudinal monitoring for rare disease patients, requiring infusion suites and specialty labs. They prioritize reliable drug supply and coordinated services to maintain adherence and reduce disruptions; Amicus reported supporting over 150 centers in 2024. Multidisciplinary teams need formal training programs and certification pathways. These centers actively participate in studies and registries to generate real-world evidence.

Patients with Fabry/Pompe (prevalence 1:40,000–1:283,000) and caregivers drive demand for durable, personalized therapies; adherence affects outcomes. Specialists and 150+ centers supported by Amicus in 2024 prescribe and manage care, requiring evidence and hub services. Payers/HTA demand $100k–150k/QALY evidence and managed-entry; labs ($23B genetic testing market in 2024) feed pipelines.

Submission preparation, inspections, and pharmacovigilance systems create sustained costs—Amicus must fund global PV infrastructure and routine FDA/EMA inspections. REMS and other risk mitigation plans require ongoing execution; the FDA listed over 60 active REMS programs in 2024. Regular audits of manufacturing and distribution partners enforce standards, while evolving regulations force frequent protocol and SOP updates.

Discovery and trials drive peak R&D spend (Phase I $1–5M; II $10–50M; III $50–300M) and rare-disease per-patient costs rise with global sites. Biologic manufacturing is capital intensive ($50M–$500M facilities) with COGS 30–60% of revenue; QC/cold-chain add ~10–20%. PV/REMS (FDA listed 60+ REMS in 2024) and commercialization/field teams create recurring operating costs.

Licensing Amicus IP and platforms generates recurring royalties, with biotech royalty rates commonly in the 5–20% range; in 2024 Amicus continued to leverage out-licenses to capture long‑tail value. Territorial deals monetize non‑core markets by transferring commercialization rights while preserving core markets and upside. Royalty monetization can fund R&D and operating growth through upfronts, milestones and royalty financing. Deal terms are calibrated to clinical and commercial risk via milestone thresholds and tiered royalty rates.

Net product sales (chronic migalastat, cipaglucosidase alfa) plus partnerships, royalties and early‑access programs form Amicus’ revenue mix; prevalence ~1 in 40,000 for Fabry and Pompe; royalties 5–20%; partnerships deliver upfronts from single‑digit millions to >100M and cost‑share 30–70%; 2024 saw continued out‑licenses and use of early‑access to build HEOR.